Genotype-based dosing strategy for azathioprine valid in RA, SLE

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1429, 2004-01, pp. : 4-4

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Genotype-Based Risk and Pharmacogenetic Sampling in Clinical Trials

By Schork Nicholas   Topol Eric  

Journal of Biopharmaceutical Statistics, Vol. 20, Iss. 2, 2010-03 ,pp. : 315-333

Taylor & Francis Ltd

Access to resources Recommend Favorite

Genotype-based therapeutic approach for colorectal cancer: state of the art and future perspectives

By Fogli Stefano   Caraglia Michele  

Expert Opinion on Pharmacotherapy, Vol. 10, Iss. 7, 2009-05 ,pp. : 1095-1108

Informa Healthcare

Access to resources Recommend Favorite

Treat-to-target strategy pays off in RA

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 659, 2012-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

Azathioprine: Diffuse alveolar haemorrhage and pancytopenia in an elderly patient with a homozygous deficient TPMT genotype: case report

By  

Reactions Weekly, Vol. 1, Iss. 1179, 2007-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

Thiopurine methyltransferase (TPMT) genotype distribution in azathioprine-tolerant and -intolerant patients with various disorders. The impact of TPMT genotyping in predicting toxicity

By Reuther Lene   Vainer Ben   Sonne Jesper   Larsen Niels-Erik  

European Journal of Clinical Pharmacology, Vol. 59, Iss. 11, 2004-01 ,pp. : 797-801

Springer Publishing Company

Access to resources Recommend Favorite